Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 3
2014 1
2016 1
2017 2
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab-induced lichen planus.
Yilmaz M, Mese SG, Celik U. Yilmaz M, et al. J Oncol Pharm Pract. 2020 Apr;26(3):758-760. doi: 10.1177/1078155219866248. Epub 2019 Aug 5. J Oncol Pharm Pract. 2020. PMID: 31382865
DISCUSSION: Skin adverse events are the most common side-effects under immunotherapy and play an important role for patients and usually develop early in the course of treatment. The most frequent skin reactions are rash, pruritus, and vitiligo. ...
DISCUSSION: Skin adverse events are the most common side-effects under immunotherapy and play an important role for patients and usually dev …
PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma.
Schmidt LS, Vocke CD, Ricketts CJ, Blake Z, Choo KK, Nielsen D, Gautam R, Crooks DR, Reynolds KL, Krolus JL, Bashyal M, Karim B, Cowen EW, Malayeri AA, Merino MJ, Srinivasan R, Ball MW, Zbar B, Marston Linehan W. Schmidt LS, et al. Urology. 2023 Sep;179:58-70. doi: 10.1016/j.urology.2023.04.035. Epub 2023 Jun 16. Urology. 2023. PMID: 37331486 Free article.
PRDM10 loss of heterozygosity was identified in kidney tumors. PRDM10 was predicted to abrogate expression of FLCN, a transcriptional target of PRDM10, which was confirmed by tumor expression of GPNMB, a TFE3/TFEB target and downstream biomarker of FLCN loss. ...
PRDM10 loss of heterozygosity was identified in kidney tumors. PRDM10 was predicted to abrogate expression of FLCN, a transcriptional …
Potential role of genetic markers in the management of kidney cancer.
Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E. Junker K, et al. Eur Urol. 2013 Feb;63(2):333-40. doi: 10.1016/j.eururo.2012.09.040. Epub 2012 Sep 24. Eur Urol. 2013. PMID: 23040205 Review.
Four major renal cell tumour subtypes can be distinguished based on morphologic and genetic characteristics. To individualise therapy and to improve the prognosis in patients with renal cell tumours, accurate subtyping, definition of individual course of disease, an …
Four major renal cell tumour subtypes can be distinguished based on morphologic and genetic characteristics. To individualise therapy and to …
Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer.
Sidana A, Kadakia M, Friend JC, Krane LS, Su D, Merino MJ, Srinivasan R. Sidana A, et al. Urol Oncol. 2017 Mar;35(3):114.e9-114.e14. doi: 10.1016/j.urolonc.2016.10.023. Epub 2016 Nov 30. Urol Oncol. 2017. PMID: 27914873 Free PMC article.
CONCLUSION: To our knowledge, this is the first systematic evaluation of the incidence, predictors, and prognostic effect of ascites in metastatic pRCC. Malignant ascites is a common manifestation of metastatic pRCC and is associated with a shorter overall survival. …
CONCLUSION: To our knowledge, this is the first systematic evaluation of the incidence, predictors, and prognostic effect of a …
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.
Roos FC, Evans AJ, Brenner W, Wondergem B, Klomp J, Heir P, Roche O, Thomas C, Schimmel H, Furge KA, Teh BT, Thüroff JW, Hampel C, Ohh M. Roos FC, et al. Am J Pathol. 2011 Feb;178(2):853-60. doi: 10.1016/j.ajpath.2010.10.033. Am J Pathol. 2011. PMID: 21281817 Free PMC article.
We show that the expression of E2-EPF ubiquitin carrier protein, which targets the principal negative regulator of hypoxia-inducible factor (HIF), von Hippel-Lindau protein, for proteasome-dependent degradation, is markedly elevated in the majority of PRCC tumors exhibiting incre …
We show that the expression of E2-EPF ubiquitin carrier protein, which targets the principal negative regulator of hypoxia-inducible factor …
Heterogeneous response to target therapy in metastatic papillary renal cell carcinoma evaluated by morphologic and metabolic multimodality imaging: A case report.
Naglieri E, Niccoli Asabella A, Nappi AG, Carella C, Ferrari C, Rubini G. Naglieri E, et al. Medicine (Baltimore). 2019 Dec;98(50):e18093. doi: 10.1097/MD.0000000000018093. Medicine (Baltimore). 2019. PMID: 31852068 Free PMC article.
RATIONALE: Papillary renal cell carcinoma (PRCC) accounts for about 15% to 20% of renal cell carcinoma and is histologically distinguished in type I and type II. The last one is associated with poorer prognosis.Treatment options for PRCC patients are surgery, immunotherapy …
RATIONALE: Papillary renal cell carcinoma (PRCC) accounts for about 15% to 20% of renal cell carcinoma and is histologically distinguished i …
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Choueiri TK, et al. J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23. J Clin Oncol. 2017. PMID: 28644771 Free article. Clinical Trial.
Furthermore, molecular characterization of MET status was more predictive of response to savolitinib than a classification based on pathology. ...
Furthermore, molecular characterization of MET status was more predictive of response to savolitinib than a classification based on p …